Respiratory Disease
               BMJ
Username: Password:
searchsite
 
Respiratory Disease » Lung Cancer »
Tuesday, 13 May, 2008


Browse by Topic
» Allergy » Asthma » Cardiothoracic Disease » Chronic Obstructive Airways Disease » Cystic Fibrosis » Diagnostics » Lung Cancer » Pneumonia » Pulmonary Disorders » Respiratory Distress Syndrome » Sleep Apnea » Tuberculosis » Ventilation

Respiratory News
Pipex Pharmaceuticals Receives FDA Orphan Drug Designation For Oral TTM For Idiopathic Pulmonary Fibrosis (IPF)
American Lung Association Founder Honored With New U.S. Postage Stamp
Research Into Cell Metabolism And Medical Injuries To Be Spearheaded By Engineer
Initiatives In Baltimore And California Address Minority Health Issues


Keeping you up to date with the latest clinical trial information

Lung Cancer

Current Strategies in the Treatment of Advanced Non-small Cell Lung Cancer
The field of lung cancer therapy remains dynamic. In the last several years, erlotinib (Tarceva, Genentech/OSI Pharmaceuticals) and pemetrexed (Alimta, Eli Lilly and Company) have gained approval for the treatment of lung cancer, and drugs such as bevacizumab have demonstrated success in combination with chemotherapy as first-line therapy against NSCLC.

The Need for an Individual Approach to Lung Cancer Treatment
Heidi Greulich and colleagues [1] have demonstrated the significance of insertion mutations in the epidermal growth factor receptor (EGFR) (exon 20) for tumorigenesis and responsiveness to tyrosine kinase inhibitors (TKIs) in lung cancers.

Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants
Tyrosine kinases (TKs) are found only in metazoans, where they regulate multiple critical multicellular functions, including growth, differentiation, apoptosis, adhesion, and mobility.
Newly FDA-approved drugs

Tarceva (erlotinib) Tablets
Approved: November 18, 2004 Company: OSI/Genentech
Treatment for: Non-Small Cell Lung Cancer (NSCLC)
Tarceva is a Human Epidermal Growth Factor Receptor Type 1/Epidermal Growth Factor Receptor (HER1/EGFR) tyrosine kinase inhibitor indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.
Guidelines Watch changeeeee
A round up of the latest Clinical Guidelines from the National Guideline Clearinghouse (NGC)

Lung Cancer

Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a clinical practice guideline
 Program in Evidence-based Care - State/Local Government Agency [Non-U.S.]. 2001 Jan 17 (revised 2006 Mar 27). 51 pages. NGC:004953

Postoperative adjuvant radiation therapy in stage II or IIIA completely resected non-small cell lung cancer
 Program in Evidence-based Care - State/Local Government Agency [Non-U.S.]. 1997 Sep 15 (revised 2005 Feb). 16 pages. NGC:004124


Upcoming Events
American Thoracic Society (ATS)
16 -  21 May 2008
Metro Toronto Convention Centre, 255 Front Street West, M5V 2W6, Toronto, Canada
International Primary Care Respiratory Group - The IPCRG Fouth World Conference
28 -  31 May 2008
Meliá Seville Dr. Pedro de Castro 1, 41004, Seville, Spain
Federation of Clinical Immunology Societies (FOCIS) 2008
05 -  09 Jun 2008
Marriot Boston, Copley Place, 110 Huntington Avenue, Boston, MA 02116, Boston, USA


  Copyright Touch Briefings 2005 - 2008    Terms & Conditions | Privacy Statement|

Articles : a b c d e f g h i j k l m n o p q r s t u v w x y z
Companies : a b c d e f g h i j k l m n o p q r s t u v w x y z
Events : a b c d e f g h i j k l m n o p q r s t u v w x y z
Keywords : a b c d e f g h i j k l m n o p q r s t u v w x y z

Specialities :
Allergy Asthma Cardiothoracic Disease Chronic Obstructive Airways Disease Cystic Fibrosis Diagnostics Lung Cancer Pneumonia Pulmonary Disorders Respiratory Distress Syndrome Sleep Apnea Tuberculosis Ventilation

Other Touch Group sites:   
Cardiology - Endocrine Disease - Oncological Disease - Gastroenterology - Respiratory Disease